Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature Read more about Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress Read more about BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020 Read more about BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate Read more about Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China Read more about BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate Read more about Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma Read more about BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature Read more about BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study Read more about Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares Read more about BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares
